CCAP Q1 2026 Earnings Call Transcript

Crescent Capital BDC reported NII of $0.38 per share, down from $0.45 sequentially, while NAV fell to $18.27 from $19.10 and nonaccruals rose to 5.7% of cost and 3.6% of fair value. Management cut the base management fee to 1.0% from 1.25% and the incentive fee to 15% from 17.5%, reset the quarterly dividend to $0.34 per share, and approved three $0.03 special dividends for 2026. Leverage increased to 1.3x versus a 1.1x-1.3x target range, though liquidity remained solid at $233 million plus a planned $100 million SPV upsize.

Analysis

CCAP’s real issue is not headline earnings volatility; it is that the fee reset and dividend reset are both lagging indicators of a portfolio that has already migrated into a lower-quality earnings regime. The permanent fee cuts help, but they also implicitly confirm management’s willingness to sacrifice fee rate for franchise durability, which is usually what you do when asset growth alone cannot bridge the gap. That should improve optics versus peers, yet it does not solve the more important problem: nonaccruals are rising in exactly the sectors where recovery timelines are longest and sponsor support is least reliable.

The second-order effect is leverage. With realizations delayed, CCAP is temporarily running a touch hot on leverage while also carrying a larger watch list, so any additional credit event would force a choice between balance-sheet discipline and opportunistic deployment. That matters because the current spread backdrop can look attractive only if you believe the portfolio can recycle capital fast enough; if exits keep slipping, the company becomes more of a slow-motion workout vehicle than a compounding BDC.

The market may be over-discounting the structural changes, but it is probably under-discounting the cadence risk. The special dividends are a clue that excess income is being returned because management does not want to promise a base payout it cannot comfortably earn through the cycle, and that usually limits multiple expansion until investors see two clean quarters of stabilization in nonaccruals and NAV. The more constructive read is that Sun Life’s deeper alignment should reduce financing and governance friction over time, but that benefit is medium-term rather than a catalyst for the next 1-2 quarters.

Key Decisions for Investors

• Avoid adding to CCAP into near-term strength; wait for evidence of two consecutive quarters of flat-to-down nonaccruals before reassessing. Near-term downside remains tied to another healthcare markdown cycle, which would likely compress the multiple faster than the fee reset can expand it.
• For existing holders, consider a covered-call overwrite on CCAP over the next 1-2 quarters to monetize elevated uncertainty while the market waits for stabilization. The dividend reset caps upside in the near term, so premium capture is more attractive than outright directional exposure.
• Pair trade: long a higher-quality BDC with lower nonaccrual intensity and stronger fee momentum versus short CCAP. The trade works if the market starts differentiating between BDCs with transitory credit noise and those with persistent healthcare/workout exposure.
• If CCAP sells off on any incremental markdown without a corresponding leverage or liquidity breach, consider a tactical long for a mean-reversion trade. The setup is that management has already de-risked the payout and fee structure, so price weakness would be more likely to overstate incremental fundamental damage.
• Monitor CCAP’s next quarter for realized exits and leverage normalization; if net leverage moves back inside target and nonaccruals plateau, the name can re-rate over 3-6 months. Until then, treat it as a hold, not a fresh long.